Results 11 to 20 of about 13,248 (184)

Aztreonam-avibactam synergy, a validation and comparison of diagnostic tools [PDF]

Frontiers in Microbiology, 2023
IntroductionAntimicrobial resistance is a growing problem that necessitates the development of new therapeutic options. Cefiderocol and aztreonam (AT) are often the last active β-lactams for treating metallo-β-lactamases (MBL)-producing Gram-negative ...
Gil Verschelden, Gil Verschelden, Maxim Noeparast, Anke Stoefs, Eveline Van Honacker, Kristof Vandoorslaer, Laura Vandervore, Margo Olbrecht, Kathleen Van Damme, Thomas Demuyser, Thomas Demuyser, Denis Piérard, Ingrid Wybo   +12 more
doaj   +2 more sources

Interactions between Avibactam and Ceftazidime-Hydrolyzing Class D β-Lactamases [PDF]

Biomolecules, 2020
Class D β-lactamases exhibit very heterogeneous hydrolysis activity spectra against the various types of clinically useful β-lactams. Similarly, and according to the available data, their sensitivities to inactivation by avibactam can vary by a
Jean-Marie Frère, Pierre Bogaerts, Te-Din Huang, Patrick Stefanic, Joël Moray, Fabrice Bouillenne, Alain Brans   +6 more
doaj   +2 more sources

Dose Selection for Ceftibuten Combined with Avibactam Tomilopil, a Potential Oral Alternative to Carbapenems for Patients with Complicated Urinary Tract Infections. [PDF]

J Clin Pharmacol
Abstract There are currently no oral treatment options for infections caused by extended spectrum β‑lactamase‐producing Enterobacterales. Avibactam tomilopil, a novel oral prodrug of avibactam, is being developed in combination with the oral cephalosporin, ceftibuten, as a potential treatment for patients with complicated urinary tract infections ...
Sahasrabudhe SA, Shoji S, Jakate AS, Abraham BK, Toussi SS, Maligalig BJ, Darekar AS, Tripathy S, Kantaridis C, Mfopou JK, Selivanova O, Bergman A, Alami NN, Singh RSP.   +13 more
europepmc   +2 more sources

A Four-Center Study on the Activity of Aztreonam and Aztreonam-Avibactam Combination Against Clinical Isolates of Gram-Negative Bacilli Producing Representatives of Ambler Class A, B, C or D β-Lactamases. [PDF]

APMIS
ABSTRACT We aimed to investigate the activity of aztreonam and aztreonam‐avibactam combination against gram‐negative bacilli producing different types of β‐lactamases. Activity of aztreonam and aztreonam‐avibactam against 166 isolates (33 AmpC‐producing, 33 ESBL‐producing, 66 carbapenemase‐producing Enterobacterales, 34 metallo‐β‐lactamase‐producing P.
Ceviz Gİ, Mirza HC, Güçlü AÜ, Şanlı ÖÖ, Azap ÖK, Sancak B, İştar EH, Başustaoğlu A.   +7 more
europepmc   +2 more sources

Integrating CRRT as a Virtual Organ Into Physiologically Based Pharmacokinetic Modeling to Optimize Antimicrobial Dosing in Septic Patients. [PDF]

CPT Pharmacometrics Syst Pharmacol
Development and application of PBPK modeling integrating CRRT as a virtual organ to characterize antimicrobial pharmacokinetics and optimize dosing in septic patients. ABSTRACT Continuous renal replacement therapy (CRRT) extracorporeal drug removal, sepsis‐related pathophysiological alterations, and reduced pathogen susceptibility to antimicrobials can
Xing Y, Zhang Y, Bai C, Qiu Y, Wang C, Chen L, Wang T, Chen J.   +7 more
europepmc   +2 more sources

Emergence of Ceftazidime-Avibactam-Induced KPC Variants (KPC-25/127) in Intracranial Infection and Implications for Clinical Management. [PDF]

Microbiologyopen
Novel KPC‐25 and first‐reported KPC‐127 sequentially evolved in one patient under CAZ‐AVI pressure, distinct mutations remodel enzyme activity to drive differential multidrug resistance. ABSTRACT The emergence of novel Klebsiella pneumoniae carbapenemase (KPC) variants contributing to clinical treatment failure poses a substantial threat to public ...
Lei K, Tian Y, Xiong C, Lei J, Chen D, Bai X, Abdul-Aziz MH, Xie J, Liu Z.   +8 more
europepmc   +2 more sources

Ceftazidima-Avibactam [PDF]

, 2021
Ceftazidime-avibactam is a combination administered intravenously, which has activity against gram-negative resistant pathogens such as, for example, Pseudomonas aeruginosas and enterobacteria resistant to carbapenem. This combination is approved for the
Ugalde Solera, Maria Natalia, Mora Salazar, Fiorella María   +1 more
core   +1 more source

Cefiderocol Resistance in Klebsiella pneumoniae Is Linked to SHV Extended-Spectrum β-Lactamase Activities and Functional Loss of the Outer Membrane Porin OmpK35

Microbiology Spectrum, 2023
Klebsiella pneumoniae AR 0047 from the CDC and FDA Antibiotic Resistance Isolate Bank is resistant to cefiderocol, a siderophore-conjugated cephalosporin.
Sun Hee Moon, En Huang
doaj   +1 more source

In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan

Microorganisms, 2020
Increasing carbapenem resistance rates worldwide underscored the urgent need of novel antimicrobials. Ceftazidime–avibactam and aztreonam–avibactam combinations are developed to combat carbapenem resistance, but biological and geographic variations must ...
Tsung-Ying Yang, Ya-Ju Hsieh, Li-Ting Kao, Guan-Hong Liu, Shao-Hsuan Lian, Liang-Chun Wang, I-Ling Lin, Yu-Tzu Lin, Sheng-Fan Wang, Sung-Pin Tseng, Po-Liang Lu   +10 more
doaj   +1 more source

Ceftazidime-avibactam plus metronidazole vs. meropenem in complicated intra-abdominal infections: Indian subset from RECLAIM

Journal of Infection in Developing Countries, 2022
Introduction: This study analyzes the safety and efficacy results of the Indian population subset from the RECLAIM trial investigating the non-inferiority of Ceftazidime-Avibactam (CAZ-AVI) plus metronidazole to meropenem and interprets its relevance.
Prithi Rodgers, Shweta Kamat, Charles Adhav   +2 more
doaj   +1 more source